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Abstract: The aim of this study was to define copy number alterations in a rare laryngeal type basaloid squamous 
cell carcinoma (laryngeal BSCC) using high throughput array comparative genomic hybridization. This is the first 
genome wide screening of a laryngeal BSCC describing the unique events of DNA copy number changes. By Nimble-
Gen Whole Genome Tiling Array CGH (consisting of 72,000 probes) we were able to identify 3,777 genes altered by 
copy number changes (1,726 genes with copy number gains and 2,051 genes with copy number with losses). The 
resolution of the array allowed us to identify a new alteration at the 17q21.31 region covering the DUSP3 gene which 
encodes the dual-specific protein phosphatase. Functional studies of the altered genes (Database for Annotation, 
Visualization and Integrated Discovery v6.7 analysis) highlighted molecular pathways including chemokine signal-
ing, cell cycle, adherent junction-, VEGF- and TGF-beta signaling pathways that might be disrupted by copy number 
alterations in laryngeal BSCC.
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Introduction
The incidence of head and neck squamous cell 
carcinoma (HNSCC) has been increasing and 
the disease has one of the lowest survival rates 
[1]. Among HNSCCs, laryngeal basaloid type 
squamous cell carcinoma (laryngeal BSCC), 
which is an aggressive variant of HNSCC, has 
an extremely low incidence rate (0.66%) [2]. 
Less than 200 cases have been published till 
now and only 48 BSCCs were localized in the 
larynx. Majority of these studies were mainly 
focusing on the histology of the tumors, while 
others aimed to identify biological markers of 
BSCCs [3-5].
Although it is widely accepted that HNSCCs 
exhibit a large number of chromosomal abnor-
malities [5, 6], chromosome alterations in 
laryngeal BSCCs have not been published yet. 
The aim of the present study was to assess 




A 60-year old male patient was diagnosed with 
dysphagia, huskiness and GERD-like symptoms 
which began few months before he was diag-
nosed with laryngeal BSCC. Clinical examina-
tions showed hypopharyngeal medial wall 
lesion involving the right larynx. Laryngo- 
microscopy showed tumor in the hypopharynx, 
which occupied the medial wall of the pyriform 
sinus, the aryepiglottic fold and the pseudovo-
cal chord. Histological investigations revealed 
basaloid squamous cell carcinoma (Figure 1). 
Ultrasonography showed lymph node of 15mm 
in size located parajugular on the right side of 
the neck. After the right functional neck dissec-
tion and the lateral pharyngotomy the tumor 
was removed by partial pharyngectomy in intra-
tracheal narcosis. Tissue samples that obtained 
from the neck were tumor-free. The patient 
received 50 Gy irradiation postoperatively (2 Gy 
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per day). The control MRI tests showed scar tis-
sue mass on the right side of the neck but no 
signs of tumor recurrence were diagnosed 
either by physical examination nor CT and MRI. 
The recurrence of the lesion was excluded by 
fine needle aspiration biopsy. A written informed 
consent was obtained from the patient to per-
form the array CGH analysis.
Genomic DNA extraction and whole genome 
tiling array CGH
A G-spin™ Genomic DNA Extraction Kit (Intron, 
Korea) was used to isolate high-molecular DNA 
from the tumor according to the protocol pro-
vided by the manufacturer. The quantity of DNA 
was determined by NanoDrop ND-1000 UV-Vis 
Spectrophotometer. DNA integrity was con-
trolled by 1.2% agarose gel electrophoresis.
Genetic aberrations were screened by 
NimbleGen CGH Whole Genome Tiling Array 
(HG18 CGH 4x72K WG Tiling v2.0) consisting of 
72,000 probes (Core Facility of the Roche 
NimbleGen, Reykjavik, Iceland). Array CGH data 
analysis was performed using a NimbleScan 
software package. Normalization and further 
statistical analyses were achieved by the Nexus 
Copy Number 5.1 software. After the exclusion 
of all data points derived from sex chromo-
somes, normalization was made by combining 
replicates within the array by their median. 
Statistical analysis of the CGH data was per-
formed by FASST2 Segmentation method. In 
order to adjust the sensitivity of the segmenta-
tion algorithm we determined the significant 
threshold at 1.0E-6, specified 1,000 kb being 
the maximum spacing between the adjacent 
probes. The minimum number of probes per 
segment required to eliminate small CNVs was 
5. Gains and losses were defined at ± 3 x SD of 
all probes and the threshold was adjusted at ± 
0.4 for both.
The gains detected by array CGH on chromo-
some 8 was validated using dual color FISH 
probes specific for the C-MYC (8q24.21) and 
the for the LPL gene (8p22). Hybridization was 
carried out according to the manufacturer’s 
instruction (Abott Molecular, IL, USA). For func-
tional representation and annotation of genes 
with copy number alterations we used the 
Database for Annotation, Visualization and 
Integrated Discovery v6.7 (freely available 
Bioinformatics Resources at http://david.abcc.
ncifcrf.gov website). Enriched Gene Ontology 
(GO) groups were ranked according to statisti-
cal significance measured by EASE score, a 
modified Fisher’s exact p-value.
Results and discussion
Copy number changes of the laryngeal BSCC 
tumor sample showed diverse DNA copy num-
ber alterations including large and regional 
gains and losses (Figure 2). The full list of copy 
number changes is summarized in Table 1. By 
detailed analysis of the array CGH data, we 
found 3,777 coding genes that were affected 
by copy number changes. Among these genes, 
1,726 exhibited copy number gains, while as 
many as 2,051 genes were involved in copy 
number losses. Although several genomic 
regions were affected (1p22.2-p21.2, 2p14-
p12, 4q12-q23, 6p25.3, 8p11.22, 14q32.33, 
15p11.1-q11.2, 15q11.2-q26.2, 16p13.3-
p11.1, 16q11.2-q24.3) by copy number losses, 
clear monosomy of full chromosomes was not 
detected on any chromosomes.
Gains involved both arms of chromosome 8, 18 
and 20. Using the Nexus software we could 
detect a small deleted (158 kb) region at 
8p11.22 covering 2 genes (ADAM3A and 
ADAM18) (Figure 3B). In order to validate the 
polisomy of chromosome 8 we used dual color 
FISH probes specific for 8p22 (LPL gene) and 
8q24.21 (C-MYC gene) (Figure 3C). Both genes 
were present in three copies in majority of the 
tumor cells.
Figure 1. Histopathological characteristics of laryn-
geal BSCC: invasive basaloid formations embedded 
in stromal background (H&E staining, x200).
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Table 1. Copy number alterations in  laryngeal basaloid squamous cell carcinoma
(A) Copy number gains 
Chromosome Cytoband Location Region Length (bp) *Number of genes involved **CNV overlap (%)
7 q11.1 - q11.21 941,545 0 97
8 p23.3 - p11.22 37,347,557 284 21
8 p11.22 - p11.1 4,365,687 31 22
8 q11.1 - q24.3 99,305,964 480 3
17 q21.31 558,792 15 0
18 p11.32 - p11.21 15,366,783 79 5
18 p11.1 - q23 59,323,179 217 8
20 p13 - p11.1 26,202,881 207 7
20 q11.1 - q13.33 33,728,458 413 5
(B) Copy number losses
Chromosome Cytoband Location Region Length (bp) *Number of genes involved **CNV overlap (%)
1 p22.2 - p21.2 11,435,375 77 1
2 p14 - p12 9,059,016 104 4
4 q12 - q23 39,861,512 192 5
6 p25.3 193,981 1 83
8 p11.22 158,476 2 78
14 q32.33 780,408 11 82
15 p11.1 - q11.2 2,623,664 5 36
15 q11.2 - q26.2 71,054,501 757 13
16 p13.3 – p11.1 35,042,190 537 21
16 q11.2 – q24.3 43,770,189 365 4
*Analyses were performed using the Nexus software; **CNV overlap is the occurrence of copy number events that exist in healthy 
donors according to the Copy Number Project database (Wellcome Trust Sanger Institute, Hinxton, UK).
Figure 2. Summary of chromosome copy number alterations of laryngeal BSCC detected by tiling array CGH. Green 
color on the right side of each chromosome represents copy number gains and red color on the left sides indicates 
copy number losses.
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A large, 942 kb copy number gain was seen on 
7q11.1-q11.21 without any coding region, while 
there was a 559 kb gain on the 17q21.31 
sequence coding 15 different transcripts. The 
increased copy number of 17q is a frequent 
event in various tumors [4, 6], but gain on the 
small 17q21.31 sequence was not described 
yet. The Whole Genome Tiling Array CGH analy-
sis allowed to map the DUSP3 gene to this 
region. Previous studies indicated that upregu-
lation of DUSP3 could enhance the signaling of 
ErbB receptors. Its direct role in the inhibition 
of JNK-dependent apoptosis was also described 
in epithelioid cancers such as prostate, cervi-
cal and non-small cell lung cancer [4].
In order to describe the characteristics and 
obtain biological relevance of the functions of 
the copy number altered genes, we determined 
the Gene Ontology (GO) groups. Based on this 
analysis 946 out of the 3,777 copy number 
altered genes had known biological functions. 
Figure 4 illustrates the 16 most relevant path-
ways that can be modified by DNA copy number 
changes, considering only molecular pathways 
that exhibit statistically significant EASE score 
(p ≤ 0.05) and involve at least 10 genes. It is 
important to note that beside chemokine sig-
naling, the cell cycle and the adherent junction 
pathway, VEGF and TGF-beta signaling path-
ways can also be influenced by DNA copy num-
ber changes. 
Enthusiastic efforts are being made to charac-
terize the genomic changes of HNSCCs and 
studies have already shown that DNA copy 
number changes are important features of 
laryngeal squamous cell carcinomas [3, 4, 6]. 
However, the laryngeal type of BSCC represents 
a rare morphologic variant of HNSCC and this 
Figure 3. Summary of copy number alterations of chromosome 8 detected by tiling array CGH and FISH. A: Copy 
number gains were found on both arms of chromosome 8 while a small region at 8p11.22 exhibited loss. B: En-
largement of the 8p11.22 identifies ADAM3A and ADAM18 genes coded by this region. C: Representative FISH 
images were obtained by dual color FISH: green fluorescence (spectrum green) indicates LPL gene (8p22) and red 
fluorescence (spectrum orange) indicates C-MYC gene (8q24.21) confirming the existence of extra copies of both 
chromosome arms.
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phenomenon might have a strong influence on 
the genetic characteristics of BSCCs. Other 
entities of BSCCs, e.g. oesophageal malignan-
cy, were also investigated by array CGH [7]. 
Despite considerable progress in the genomic 
approach, the published data do not suggest 
any distinct genetic alteration of laryngeal 
BSCCs. Our study has revealed unique genomic 
changes and highlighted that the number of 
alterations were significantly higher in the BSCC 
than in other types of head and neck cancers.
While 8q gain is considered to be an important 
genetic alteration of laryngeal HNSCC [6-8], we 
have shown that both arms of chromosome 8 
can be overrepresented in laryngeal BSCC. It is 
interesting that the only common genetic alter-
ation of laryngeal BSCC with esophageal BSCC 
is the loss of 8p11.2 [6], however, this region is 
due to copy number variants in healthy individ-
uals as well, therefore we assume that the 
8p11.2 gain might not be a disease specific 
genetic marker, however, this assumption 
should be tested. Considering the biological rel-
evance of the protein coding genes disturbed 
by copy number alterations, we performed GO 
enrichment analysis and identified several sig-
naling pathways involving VEGF and TGF-beta 
signaling. The altered functions of these path-
ways have been previously suggested to play 
an important role in HNSCC and associated 
with poor prognosis. Furthermore, similarly to 
other epitheloid tumors, antisense therapy 
against VEGF is under development in HNSCC 
[4, 9, 10], and the downregulation of TGF-beta 
is also well-defined characteristic of HNSCC 
[11].
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